Mithra Pharmaceuticals SA (MITPF)
USD 6.75
(0.0%)
USD 6.75
(0.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -2.41 Million | -71.36 Million | -97.92 Million | -102.2 Million | -56.28 Million | 93.73 Thousand |
| Net Income | -191.54 Million | -63.8 Million | -132.84 Million | -112.67 Million | -29.81 Million | -31.55 Million |
| Depreciation & Amortization | 13.48 Million | 12.77 Million | 11.85 Million | 12.08 Million | 6.48 Million | 3.25 Million |
| Deferred income taxes | - | -60.85 Million | -17.77 Million | -45.44 Million | - | - |
| Stock-based compensation | 5.01 Million | 1.98 Million | 1.06 Million | 7.26 Million | 4.89 Million | - |
| Change in working capital | - | -33.31 Million | 6.99 Million | -14.01 Million | -59.47 Million | -19.12 Million |
| Other non-cash items | 170.63 Million | 71.84 Million | 32.78 Million | 50.57 Million | 98.96 Million | 61.51 Million |
| Investing Cash Flow | 3.81 Million | -27.28 Million | -62.15 Million | -19.83 Million | -22.96 Million | 6.36 Million |
| Investments in PPE | - | -27.46 Million | -24.07 Million | -19.85 Million | -17.34 Million | -11.54 Million |
| Acquisitions | - | 180.87 Thousand | - | 28.14 Thousand | - | 22.12 Million |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | 3.81 Million | -1070.00 | -38.07 Million | 1.00 | -5.61 Million | -4.21 Million |
| Financing Cash Flow | -22.67 Million | 93.89 Million | 39.79 Million | 230.87 Million | 1.54 Million | 88.15 Million |
| Debt repayment | - | -48.61 Million | -38.36 Million | -1.07 Million | -4.57 Million | -2.19 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | 53.55 Million | 10.47 Million | 230.18 Million | 190.82 Thousand | 85.96 Million |
| Other Financing Activities | -22.67 Million | 88.95 Million | 67.68 Million | 1.75 Million | 8.36 Million | - |
| Accounts receivables | - | -45.46 Million | 18.94 Million | 8.72 Million | -66.18 Million | 11.55 Million |
| Accounts payables | - | 19.51 Million | -2.32 Million | 637.46 Thousand | 12.63 Million | -10.34 Million |
| Inventory | - | -7.35 Million | -9.62 Million | -23.37 Million | -5.92 Million | -8.69 Million |
| Other working capital | - | - | -2.00 | 1.00 | - | -11.64 Million |
| Cash at beginning of period | 30.28 Million | 37.36 Million | 169.67 Million | 55.81 Million | 135.97 Million | 43.45 Million |
| Cash at end of period | 9.91 Million | 30.27 Million | 37.36 Million | 169.67 Million | 55.81 Million | 135.97 Million |
| Capital Expenditure | - | -27.46 Million | -24.07 Million | -19.85 Million | -17.34 Million | -11.54 Million |
| Effect of forex changes on cash | -38.63 Thousand | -147 Thousand | 21 Thousand | -0.23 | 0.16 | - |
| Net cash flow / Change in cash | -20.37 Million | -7.09 Million | -132.31 Million | 113.86 Million | -80.16 Million | 92.51 Million |
| Free Cash Flow | -2.41 Million | -98.82 Million | -122 Million | -122.05 Million | -73.63 Million | -11.45 Million |
| Breakdown | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 FY |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -191.5 Million | -67.91 Million | -65.03 Million | -55.04 Million | -27.37 Million | -63.8 Million |
| Depreciation & Amortization | 13.48 Million | 3.34 Million | 3.2 Million | 6.71 Million | 3.33 Million | 12.77 Million |
| Deferred income taxes | - | - | - | - | - | -60.85 Million |
| Stock-based compensation | 5.01 Million | 2.84 Million | 2.72 Million | -338.82 Thousand | -336.8 Thousand | 1.98 Million |
| Change in working capital | - | -34.93 Million | -33.44 Million | 56.24 Million | 34.32 Million | -33.31 Million |
| Other non-cash items | 202.57 Million | 87.58 Million | 83.87 Million | -40.96 Million | -2.22 Million | 71.84 Million |
| Investing Cash Flow | 3.81 Million | 602.23 Thousand | 576.69 Thousand | 2.57 Million | 1.28 Million | -27.28 Million |
| Investments in PPE | - | 166.7 Thousand | 159.63 Thousand | -6.1 Million | -163.79 Thousand | -27.46 Million |
| Acquisitions | - | - | - | - | - | 180.87 Thousand |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | 11.13 Million | - | - |
| Other Investing Activities | 3.81 Million | 435.52 Thousand | 417.06 Thousand | -2.45 Million | 1.44 Million | -1070.00 |
| Financing Cash Flow | -22.66 Million | 326.23 Thousand | 312.4 Thousand | -17.29 Million | -11.45 Million | 93.89 Million |
| Debt repayment | - | - | - | -16.62 Million | - | -48.61 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | -1.37 Million | -1.32 Million | - | - | - |
| Common Stock Issuance | - | - | - | 2.72 Million | - | 53.55 Million |
| Other Financing Activities | -22.67 Million | 1.7 Million | 1.63 Million | -91.62 Thousand | -11.45 Million | 88.95 Million |
| Accounts receivables | - | -34.27 Million | -32.82 Million | 67.72 Million | 33.67 Million | -45.46 Million |
| Accounts payables | - | - | - | -12.77 Million | - | 19.51 Million |
| Inventory | - | -656.32 Thousand | -628.5 Thousand | 1.29 Million | 644.86 Thousand | -7.35 Million |
| Other working capital | - | - | - | - | - | - |
| Cash at beginning of period | 30.27 Million | 25.86 Million | - | 30.27 Million | - | 37.36 Million |
| Cash at end of period | 9.91 Million | 9.91 Million | -7.78 Million | 25.86 Million | -2.47 Million | 30.27 Million |
| Capital Expenditure | - | 166.7 Thousand | 159.63 Thousand | -6.1 Million | -163.79 Thousand | -27.46 Million |
| Effect of forex changes on cash | -38.63 Thousand | 1104.00 | 1057.19 | -20.18 Thousand | -20.06 Thousand | -147 Thousand |
| Net cash flow / Change in cash | -20.36 Million | -15.95 Million | -7.78 Million | -4.4 Million | -2.47 Million | -7.09 Million |
| Free Cash Flow | -2.41 Million | -8.89 Million | -8.51 Million | 3.66 Million | 7.55 Million | -98.82 Million |
PNSE
ORLCF
2509
MFSL
2795
1389